Skip to content

Metabolic & GLP-1 · Reference monograph

Dual GLP-1 and glucagon receptor agonist

Reference compound — not available from Purity Peptides. Shown for research context.

Overview

Mazdutide is a dual GLP-1 and glucagon receptor agonist modelled on oxyntomodulin, a naturally occurring gut hormone with activity at both receptors. Originally discovered by Eli Lilly, it has been developed in China by Innovent Biologics, with a fatty-acid modification that extends its half-life for once-weekly use in clinical trials.

Phase 3 trials in Chinese adults — GLORY in obesity and DREAMS in type 2 diabetes — reported clinically meaningful reductions in body weight and glucose measures, along with reductions in liver fat. Based on these data, Chinese regulators approved mazdutide in 2025. It has not been approved by the FDA, EMA or ANVISA. Research interest focuses on how adding glucagon-receptor activity alters energy expenditure and hepatic metabolism compared with GLP-1 agonism alone. Our product is the research-grade reference compound for laboratory study.

Mechanism studied

  1. Mazdutide
  2. GLP-1R + GCGR
  3. Satiety & energy expenditure
  4. Weight & glucose endpoints

Mazdutide activates the GLP-1 receptor, enhancing glucose-dependent insulin secretion, slowing gastric emptying and reducing appetite via central pathways. Concurrent glucagon-receptor activation in the liver increases fatty-acid oxidation and may raise energy expenditure, contributing to reductions in liver fat and body weight. The GLP-1 component counterbalances the hyperglycaemic tendency of glucagon signalling. This design mirrors the dual pharmacology of endogenous oxyntomodulin while providing the stability needed for sustained receptor exposure in long-term studies.

Research highlights

  • 01Oxyntomodulin-inspired dual GLP-1/glucagon receptor agonist
  • 02GLORY and DREAMS phase 3 trials conducted in Chinese adults
  • 03Approved in China in 2025; not approved by FDA, EMA or ANVISA
  • 04Reductions in liver fat reported alongside weight and glucose effects
  • 05Representative of the GLP-1/glucagon co-agonist class

Latest published research

58 papers on PubMed →

  1. The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications

    Chen Z et al. · Journal of diabetes and metabolic disorders · 2026 Dec · PMID 42871568

  2. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial

    Hsia SH et al. · The lancet. Diabetes & endocrinology · 2026 Nov · PMID 42628555

  3. Effectiveness of the Dual GLP-1R/GCGR Agonist Mazdutide in GSD IXc: A Case Report

    Chen Y et al. · Journal of clinical medicine · 2026 Oct 20 · PMID 42941641

  4. The GLP-1R/GCGR Dual Agonist Mazdutide Attenuates Liver Steatosis and Decreases Circulating Cholesterol Levels in Mice With Metabolic Dysfunction-Associated Steatotic Liver Disease

    Yu L et al. · Diabetes, obesity & metabolism · 2026 Oct 14 · PMID 42875732

  5. The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction-Associated Steatohepatitis-A Narrative Review with a Translational Focus

    Ard JD et al. · Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026 Oct 11 · PMID 42860310

  6. Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application

    Tong LH et al. · Journal of chromatography. A · 2026 Oct 11 · PMID 42603384

  7. Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis

    Kamrul-Hasan ABM et al. · Diabetes, obesity & metabolism · 2026 Oct · PMID 42410325

  8. Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis

    Amjad MM et al. · Diabetes, obesity & metabolism · 2026 Sep 29 · PMID 42811393

Live feed from PubMed (NCBI) for “Mazdutide”, updated 2026-10-30. Listing a paper is not an endorsement of its findings.

Registered studies

44 on ClinicalTrials.gov →

From the public ClinicalTrials.gov registry for “Mazdutide”, updated 2026-10-30. Shown for research context only; Purity Peptides products are not for human use.

Key references

  1. [1]Phase 3 trials published (GLORY / DREAMS)
  2. [2]PubMed — reviews on mazdutide and obesity

FAQ

  • Mazdutide received regulatory approval in China in 2025 following the GLORY and DREAMS phase 3 programmes. It remains investigational in the United States, Europe and Brazil. Our product is a research-grade reference peptide for laboratory studies only.

  • Lyophilized Mazdutide is normally kept sealed at −20 °C, protected from light and moisture. Once reconstituted for laboratory work, aliquots are held at 2–8 °C for short-term use or frozen, avoiding repeated freeze–thaw. Follow the lot-specific guidance on the certificate of analysis.

  • Every lot of Mazdutide ships with a certificate of analysis reporting HPLC purity, mass-spectrometry identity against the expected molecular weight, appearance and lot number. Match the COA lot to the vial label and keep it with your experimental records.

FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.

Related compounds

WhatsApp